Novartis reports durable Cosentyx responses in psoriasis

Novartis AG (NYSE:NVS; SIX:NOVN) said Cosentyx secukinumab produced durable responses in an extension of the Phase III SCULPTURE study to treat moderate-to-severe plaque psoriasis, with 88.5% of patients achieving a PASI 75 after four years of treatment.

The company said the proportion of patients achieving PASI 100 was maintained over the four-year extension study (43.8% at one year vs. 43.5% at four years), as was the proportion achieving PASI 90 (68.5% at one year vs. 66.4% at four years). Novartis said average improvement in PASI score was maintained at over 90%. Cosentyx's safety profile was consistent with previous Phase III studies. ...